Unloxcyt (cosibelimab-ipdl) is now available in the US for healthcare professionals to prescribe for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (llaCSCC) who are not candidates for curative surgery, the Mumbai-based drug major said in a statement.
The drug has been named Unloxcyt. Representation/File pic
Sun Pharmaceutical Industries on Friday said it has launched skin cancer drug Unloxcyt in the US market.
Unloxcyt (cosibelimab-ipdl) is now available in the US for healthcare professionals to prescribe for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (llaCSCC) who are not candidates for curative surgery, the Mumbai-based drug major said in a statement.
“Unloxcyt is an evolution in checkpoint inhibition, combining durable efficacy with a proven tolerability profile for a group of aCSCC patients who traditionally would struggle to strike that therapeutic balance,” said Richard Ascroft, CEO of Sun Pharma North America.
The medication is available through a limited distribution network of authorised speciality distributors, and one contracted speciality pharmacy.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
Subscribe today by clicking the link and stay updated with the latest news!" Click here!
